Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG1SXD)

• Drug Name: CXCL8 Drug Info
• Synonyms: Interleukin-8; CHEMBL411250; interleukin-8; IL-8

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 74974005
  TTD Drug ID: DMG1SXD

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[3]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[4]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[3]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[5]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[6]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[7]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[11]

Drug(s) Targeting C-X-C chemokine receptor type 4 (CXCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Plerixafor	DMCJN1P	Non-hodgkin lymphoma	2B33.5	Approved	[12]
Motixafortide	DMW34B1	Multiple myeloma	2A83	Approved	[13]
Ulocuplumab	DM6PMNR	Multiple myeloma	2A83	Phase 3	[14]
Balixafortide	DMUOFAC	Metastatic breast cancer	2C6Y	Phase 3	[15]
AMD-070	DMVOY6B	Whim syndrome	4A00.Y	Phase 3	[16]
TG-0054	DM2ZLWH	Macular degeneration	9B78.3	Phase 2	[17]
POL-6326	DM4OT29	Human immunodeficiency virus infection	1C62	Phase 2	[18]
CTCE-9908	DM95XR8	Sarcoma	2A60-2C35	Phase 1/2	[19]
USL311	DM6HPEC	Recurring respiratory infection	CA07-CA45	Phase 1/2	[20]
GMI-1359	DML1KSA	Breast cancer	2C60-2C65	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Agonist	[2]
C-X-C chemokine receptor type 4 (CXCR4)	TTBID49	CXCR4_HUMAN	Agonist	[2]

References

• [1] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [2] Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.
• [3] 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
• [4] Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
• [5] CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
• [6] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [7] Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
• [8] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [11] A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.
• [12] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [13] The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [16] Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
• [17] CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
• [18] CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
• [19] A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Clinical pipeline report, company report or official report of GlycoMimetics.